Blog

Naveen Pemmaraju: Nitin Jain and Rami Komrokji kick off the US AML-ALL Focus meeting

Collage photo of Nitin Jain and Rami Komrokji

Jul 14, 2024, 07:11

Naveen Pemmaraju: Nitin Jain and Rami Komrokji kick off the US AML-ALL Focus meeting

Naveen Pemmaraju shared a post on X: .

“Superb talks by Nitin Jain on Highlights of CLL and Rami Komrokji on Highlights in MDS to kick off our US AML-ALL Focus meeting hosted by Ryan F and MD Education team.

Thanks to moderators Dr Jabbour, Eunice Wang and Naval Daver.”

Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

Nitin Jain is a Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, USA. He leads the CAR T program for the Leukemia Department, MDACC.

Specializing in acute and chronic leukemias, notably CLL and ALL, his research focuses on new drug development, reflected in his leadership of multiple investigator-initiated clinical trials.

Rami Komrokji is the Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center and a Professor in Medicine and Oncologic Sciences at the University of South Florida.

He specializes in myeloid neoplasms, having led numerous clinical trials that contributed to the FDA approvals of luspatercept for myelodysplastic syndromes and pacritinib for myelofibrosis.

Dr. Komrokji’s research focuses on Phase I and II clinical trials and outcome research in hematologic malignancies, particularly myelodysplastic syndromes, acute myeloid leukemias, and myeloproliferative neoplasms.